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Congenital anomalies that arediagnosed in at least 120,000US infants every year are the
leading cause of infant death and contribute to disability and pediatric hospitalizations.
Several large-scale epidemiologic studies have provided substantial evidence of an
association between congenital anomalies and cancer risk in children, suggesting
potential underlying cancer-predisposing conditions and the involvement of develop-
mental genetic pathways. Electronic medical records from 1,107 pediatric, adolescent,
and young adult oncology patients were reviewed. The observed number (O) of
congenital anomalies among children with a specific pediatric cancer subtype was
compared to the expected number (E) of anomalies basedon the frequency of congenital
anomalies in theentire studypopulation.TheO/E ratioswere testedfor significanceusing
Fisher’s exact test. The Kaplan–Meier method was used to compare overall and
neurological malignancy survival rates following tumor diagnosis. Thirteen percent of
patients had a congenital anomaly diagnosis prior to their cancer diagnosis. When
stratified by congenital anomaly subtype, there was an excess of neurological anomalies
amongchildrenwithcentral nervous systemtumors (O/E = 1.56,95%CI1.13–2.09).Male
pediatric cancer patients were more likely than females to have a congenital anomaly,
particularly those <5 years of age (O/E 1.35, 95%CI 0.97–1.82). Our study provides
additional insight into the association between specific congenital anomaly types and
pediatric cancer development. Moreover, it may help to inform the development of new
screening policies and support hypothesis-driven research investigating mechanisms
underlying tumor predisposition in children with congenital anomalies.
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1 | INTRODUCTION
The etiology of most childhood malignancies is poorly understood.
Unlike adult cancers at the molecular level, pediatric cancers have a
relative paucity of acquired somaticmutations (Chmielecki et al., 2017;
Vogelstein, Papadopoulos, Velculescu, Zhou, & Kinzler, 2013), and
these mutations, on their own, generally do not generate tumors that
phenocopy pediatric cancer in animal models (Bueno et al., 2013;
Bursen et al., 2010; Montes et al., 2011). This suggests additional
germline genetic or epigenetic variation is required for tumor
formation ormalignant transformation. Recent reports have suggested
that 8–30% of pediatric oncology patients have a cancer predisposi-
tion (Knapke, Nagarajan, Correll, Kent, & Burns, 2012; Zhang et al.,
2015). It is well known that children with Down syndrome have an
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increased risk for leukemia (Mili, Khoury, Flanders, & Greenberg, 1993;
Mili, Lynch, Khoury, Flanders, & Edmonds, 1993; Miller, 1963; Nishi,
Miyake, Takeda, & Hatae, 2000), while those diagnosed with
Beckwith–Wiedemann syndrome are at an increased risk for
developing embryonal tumors, especially Wilms tumors (DeBaun &
Tucker, 1998; Riccardi, Sujansky, Smith, & Francke, 1978). In addition
to known cancer predisposition syndromes, there is growing literature
supporting an association between sporadic birth defects and pediatric
malignancy.
Diagnosed in at least 120,000 US babies each year, congenital
anomalies are the leading cause of infant death and contribute to
disability and pediatric hospitalizations (Centers for Disease Control
and Prevention, 2008; Hoyert, Mathews, Menacker, Strobino, &
Guyer, 2006; Mathews and MacDorman, 2012; Rosano, Botto,
Botting, & Mastroiacovo, 2000; Yoon et al., 1997). Multiple linkage
studies have reported a prevalence of 2–3% of children with
congenital anomalies in the general population (Hoyert et al., 2006;
Yoon et al., 1997). Several large-scale epidemiologic studies have
provided substantial evidence of an association between congenital
anomalies and cancer risk in children (Agha et al., 2005; Altmann,
Halliday, & Giles, 1998; Bjorge, Cnattingius, Lie, Tretli, & Engeland,
2008; Botto et al., 2013; Carozza, Langlois, Miller, & Canfield, 2012;
Hall, Ritz, Cockburn, Davidson, & Heck, 2017; Janitz et al., 2016; Mili,
Khoury et al., 1993); Narod, Hawkins, Robertson, & Stiller, 1997;
Rankin, Silf, Pearce, Parker, & Ward Platt, 2008; Rios et al., 2016;
Windham, Bjerkedal, & Langmark, 1985). Studies have demonstrated
significant associations specifically between neurological congenital
anomalies and pediatric cancer (Altmann et al., 1998; Bjorge et al.,
2008; Botto et al., 2013; Carozza et al., 2012; Narod et al., 1997), with
some suggesting a specific link between neurological malformations
and central nervous system tumors (Agha et al., 2005; Altmann et al.,
1998; Bjorge et al., 2008; Narod et al., 1997).
While the reported relationshipsbetweencongenital anomalies and
cancer risk are variable, these associations suggest that some individuals
with congenital anomalies may have underlying cancer-predisposing
conditions. Further investigation into the associations between specific
anomalies and tumor subtypes may refine our understanding of
pediatric, adolescent, and young adult (AYA) cancer development.
Therefore,weconducteda retrospective study, reviewing theelectronic
medical records for pediatric and AYA oncology patients seen at a large
academic pediatric medical center to quantify associations between
congenital anomalies and pediatric malignancies.
2 | MATERIALS AND METHODS
2.1 | Study cohort
The study population consisted of all pediatric and AYA (ages 0–23
years) oncology patients diagnosed from January 1, 2004 toDecember
31, 2014 at St. Louis Children’s Hospital with no selection for
demographics, insurance provider or other criteria other than cancer
with or without a congenital anomaly. Information ascertained from
review of both in- and outside-hospital electronic medical records
were included in the analysis. Patients diagnosed with chromosomal
anomalies, cancer predisposition syndromes, or benign tumors were
excluded based on genetic sequencing results, pathology reports, and
physician notes documenting clinical criteria for diagnosis. In addition,
patients diagnosed with a benign tumor according to the ICD-O-3
classification criteria (Steliarova-Foucher, Stiller, Lacour, & Kaatsch,
2005) or who had less than one year of documented follow-up were
excluded from the analysis. The Washington University in St. Louis
Institutional Review Board approved this study.
Study data were collected and managed using REDCap electronic
data capture tools (Harris et al., 2009). Pathology and radiologic
reports were reviewed to confirm tumor diagnosis and histology for
classification purposes. Site and morphology codes were assigned
according to the International Classification of Diseases-Oncology,
third edition (ICD-O-3). Tumors and subtypes, when sample sizes were
large enough, were then classified according to the International
Classification of Childhood Cancer, third edition (ICCC-3) (Steliarova-
Foucher et al., 2005). Additional demographic characteristics were also
recorded, including sex, race, age, treatment(s) received, length of
follow-up, and other long-term outcomes related to the primary tumor
diagnosis.
2.2 | Congenital anomaly ascertainment
Congenital anomalies were identified through text abstractions from
physician letters, operative summaries, clinical notes, physician
consults, and outside hospital records when available. A congenital
anomaly was only included in this study if it occurred prior to and was
not an associated functional symptom of the primary tumor diagnosis
and the anomaly met at least one diagnostic code in the congenital
anomalies chapter of the ninth revision of the International
Classification of Diseases (ICD-9). Patients who were documented
to have more than one congenital anomaly subtype were included in
analysis for each subtype, but were only included once when
calculating the overall prevalence of congenital anomalies in this
study population.
All congenital anomaly indications were classified according to the
standardized birth defects classification established by the National
Birth Defects Prevention Network Appendix 3.1 “Birth Defects
Descriptions for NBDPN Core, Recommended, and Extended Con-
ditions” (https://www.nbdpn.org/docs/Appendix_3_1_BirthDefectsD
escriptions2015_2016DEC14.pdf). Collaboration with the Division of
Pediatric Neurology at Washington University in St. Louis also
identified additional diagnoses to include as neurodevelopmental
conditions, such as developmental delay, hydrocephalus, cerebral
palsy, epilepsy and recurrent seizures, convulsions, and anomalies of
skull and facial bones. These conditions were also reviewed for
diagnosis prior to the primary tumor diagnosis, as well as excluding
those diagnoses that were also presenting functional symptoms of the
tumor itself (e.g., hydrocephalus secondary to mass effect from a brain
tumor). In addition, classification of these conditions using ICD-9
billing codes was reviewed and established with the Division of
Pediatric Neurology faculty prior to initiating electronic record
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reviews. Based on sample size, neurological anomalies were further
sub-classified by developmental delay, movement disorder, and
structural defects.
2.3 | Statistical analysis
Bivariate analyses comparing basic demographic factors between
patients comprising the pediatric and AYA cancer cohort with and
without a congenital anomaly, as well as any differences among the
different anomaly and tumor subtypes, were calculated using χ2 or
Fisher’s exact test when sample sizes were less than 5. Additional
comparisons were made based on age at diagnosis and gender. The
follow-up time was measured from the age at primary tumor diagnosis
until the date of last clinic visit, death, or until December 31, 2015,
which provided at least one year of follow-up for each patient in the
study. Loss of follow-up was noted for those patients who were last
seen in a clinic visit but were subsequently deceased with no recorded
date of death on file or who chose to pursue further medical
management at another institution.
To determine whether there was an excess of congenital
anomalies among a particular pediatric or AYA cancer subtype, the
observed number of congenital anomalies among patients with cancer
subtype was compared to the expected frequency of the anomalies
among children in the entire study population, based on previously
describedmethods (Narod et al., 1997). The observed-to-expected (O/
E) ratios were tested for significance using the Fisher exact test (http://
www.openepi.com/SMR/SMR.htm) (Soe & Sullivan, 2006). Compar-
isons were made by primary tumor diagnosis, congenital anomaly
subtype, gender, and age at diagnosis.
Sensitivity analyses were conducted using patients diagnosed
with leukemias as the reference group for calculation of the expected
number of congenital anomalies among patients with a specific cancer
subtype. Our rationale for using leukemia cases as an alternative
comparison group is because leukemias are primarily associated with
Down syndrome (Botto et al., 2013; Dawson, Charles, Bower, de Klerk,
&Milne, 2015;Harris et al., 2009;Hoyert et al., 2006;Miller, 1963; Shu
et al., 1988). Therefore, wemade the assumption that the frequency of
congenital anomalies observed in our leukemia patient sub-population
(after excluding Down syndrome leukemia cases) may provide a more
accurate estimate of the prevalence of congenital anomalies observed
in the general population (after applying the same exclusions we
applied in this study).
3 | RESULTS
Distinct ICD-9 codes were selected to identify children with various
congenital anomalies that were diagnosed prior to a cancer diagnosis.
Of 1,107 pediatric and AYA oncology patients, 141 (13%) were
identified with a congenital anomaly prior to their primary tumor
diagnosis (Table 1). Due to a small sample size, gastrointestinal and
genitourinary anomalies were collapsed together (Table 2). In addition,
there were seven patients who were diagnosed with more than one
congenital anomaly. While more males than females had a congenital
anomaly prior to their primary tumor diagnosis, the distribution of sex,
race, age at primary tumor diagnosis, primary tumor subtype, follow-
up, and vital status were not significantly different between pediatric
and AYA oncology patients with and without a congenital anomaly.
TABLE 1 Descriptive characteristics of 1,107 oncology patients








Characteristic N (%) N (%)c
Sex
Male 638 (58) 88 (14)
Female 469 (42) 53 (11)
Race
White 915 (83) 119 (13)
Black 138 (12) 16 (12)
Other 42 (4) 3 (7)
Unknown 12 (1) 3 (25)
Age at primary cancer diagnosis (y)
<5 353 (32) 53 (15)
5–9 247 (22) 26 (11)
10-14 285 (26) 32 (11)
15+ 222 (20) 30 (14)
Primary cancer diagnosis
Leukemia 270 (24) 32 (12)
Lymphoma 109 (10) 10 (9)
Central nervous system 367 (33) 53 (14)
Peripheral nervous system 70 (6) 11 (16)
Renal 45 (4) 7 (16)
Bone 65 (6) 2 (3)
Soft tissue sarcoma 79 (7) 13 (16)
Germ cell 46 (4) 6 (13)
Othera 56 (5) 7 (13)
Follow-up (y)b
<5 606 (55) 79 (13)
5–9 453 (41) 53 (12)
10+ 48 (4) 9 (19)
Vital status
Alive 957 (86) 127 (13)
Deceased 106 (10) 6 (6)
Lost to follow-up 44 (4) 8 (18)
aOther cancers include tumors of the thyroid, endocrine glands, liver,
nasopharyngeal cavity, and skin.
bLength of follow-up calculated from date of primary tumor diagnosis to
earliest occurrence of date of last follow-up, death, or end of study
(December 31, 2015).
cPercent of patients with a congenital anomaly among total number of
patients within the same demographic subgroup.
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Among pediatric cancer patients who were identified as having a
congenital anomaly there was a higher percentage of central nervous
system (CNS), peripheral nervous system (PNS), renal, and soft tissue
tumor (STS) diagnoses than in patients who were not identified as
having a congenital anomaly.
Overall, there was a deficiency of congenital anomalies in children
diagnosed with bone tumors (O/E 0.24, 95%CI 0.04–0.80) (Figure 1).
Excesses of congenital anomalies were noted for pediatric cancer
patients diagnosed with CNS, PNS, renal, and STS tumors. Analyses
conducted by congenital anomaly subtype indicated a significantly
increased excess of neurological anomaly (O/E 1.54 95%CI 1.09–2.11)
in patients with CNS tumors. There was also an excess of neurological
anomalies in patients with PNS and soft tissue tumors and of
cardiovascular anomalies in children diagnosed with leukemias (O/E
1.90 95%CI 1.03–3.24). No significant associations were noted for GI/
GU, musculoskeletal, or other anomalies but notably there were
positive associations for leukemias and renal tumors and all three
anomaly subtypes.
Additional stratification by CNS tumor and neurological anomaly
subtype was conducted to evaluate whether the observed association
was driven by one ormore specific subtypes. There was a deficiency of
neurological anomalies in astrocytoma and ependymoma cases with
positive associations noted for embryonal tumors, gliomas, and other
CNS tumors (Table 3). In addition, there was an excess of embryonal
and other tumors associated with developmental delay, gliomas, and
other tumors with structural defects and with movement disorders.
Further analyses by specific anomaly diagnoses could not be
conducted due to limited sample size. Among the leukemia subtypes,
9 of the 12 cardiovascular anomalies were diagnosed in patients who
had post-transplant lymphoproliferative disease (PTLD) secondary to
prolonged immunosuppression (data not shown). Sensitivity analyses
excluding all PTLD cases from the leukemia population resulted in a
non-significant inverse association between leukemia and cardiovas-
cular anomalies (O/E 0.92, 95%CI 0.23–2.49).
Additional subgroup analyses stratified by sex for congenital
anomaly subtype and age at diagnosis were conducted. Overall, there
was a trend towards a slight excess of congenital anomalies among
males (O/E 1.09, 95%CI 0.88–1.33) but not females (O/E 0.89, 95%CI
0.67–1.15). When stratified by congenital anomaly subtype, there was
a consistent excess of congenital anomalies among males for
neurological (O/E 1.18, 95%CI 0.88–1.55), cardiovascular (O/E 1.12,
95%CI 0.66–1.78), gastrointestinal/genitourinary (O/E 1.51, 95%CI
0.91–2.36), and other anomalies (O/E 1.45, 95%CI 0.68–2.76). A non-
significant excess of musculoskeletal anomalies was observed among
females (O/E 1.56, 95%CI 0.76–2.85). When stratified by age at
diagnosis, there was an overall excess of patients <5 years of age with
any congenital anomaly (O/E 1.18, 95%CI 0.89–1.53, data not shown).
Male patients <5 years of age with any congenital anomaly and
diagnosed with their primary tumor were more common than females
at the same age (O/E 1.35 95%CI 0.97–1.82) (Table 4).
Sensitivity analyses conducted using the leukemia patient
subpopulation to calculate expected congenital anomaly numbers
were consistent with the results previously reported above (Table 5).
TABLE 2 Distribution of congenital anomalies by subtype and ICD-9




315.0–315.9: Specific developmental delays 17




331.4: Obstructive hydrocephalus 1
343.0–343.9: Cerebral palsy 5
345.0–345.9: Epilepsy and recurrent seizures 21
779.0: Convulsions in newborn 1
780.3: Convulsions 10
Structural defects
348.4: Arnold–Chiari malformation 3
741.0–741.9: Spina bifida 3




745.0–745.9: Bulbis cordis/cardiac septal
closure anomaly
8
746.0–746.9: Other congenital anomaly of the
heart
12
747.0–747.9: Other congenital anomaly of the
circulatory system
Gastrointestinal/genitourinary anomalies 4
750.0–750.9: Other congenital anomaly of
upper alimentary
8
751.0–751.9: Other congenital anomaly of
digestive system
6
752.0–752.9: Congenital anomaly of genital
organs
5







755.0–755.9: Other congenital anomalies of
limbs
4
756.0–756.9: Other congenital musculoskeletal
anomalies
6
658.8: Amniotic bands 1
Other anomalies 2
743.0–743.9: Congenital anomaly of eye 2




ICD-9, international classification of diseases; ninth revision; N, number of
patients with each congenital anomaly diagnosis code.
aA total of 7 patients had more than one congenital anomaly diagnosis.
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Notably, there were stronger associations between neurological
anomalies CNS tumors (O/E 2.54, 95%CI 1.80–3.47), PNS tumors
(O/E 3.21, 95%CI 1.57–5.90), and STS (O/E 2.67, 95%CI 1.24–5.06). In
addition, there was a consistent excess of neurological anomalies
regardless of primary tumor diagnosis by sex, with a slightly higher
burden among males (O/E 1.93, 95%CI 1.44–2.55) compared to
females (O/E 1.50, 95%CI 1.01–2.15).
Despite small sample sizes, using the Kaplan–Meier method to
calculate survival by congenital anomaly indication was also noted to
be slightly better for oncology patients diagnosed with a congenital
anomaly compared to those without (at 10 years: 86.9% vs. 81.0%,
respectively; p:0.20). In addition, survivalwas similar for patientswith a
neurological malignancy when stratified by congenital anomaly
indication (at 10 years: 79.9% vs. 81.9%, respectively; p:0.89). No
other significant differences in survival were noted when stratified by
tumor or anomaly subtype (data not shown).
4 | DISCUSSION
Increased risks for subsequent CNS, neuroblastoma, germ cell, and
rhabdomyosarcoma tumors among children with congenital anomalies
have been previously reported, as well as specific risks for those with a
neurological, circulatory, genitourinary, digestive, and musculoskeletal
abnormality (Agha et al., 2005; Altmann et al., 1998; Bjorge et al., 2008;
Botto et al., 2013; Carozza et al., 2012; Fisher et al., 2012; Narod et al.,
1997; Rios et al., 2016). However, few studies have provided specific
anomaly/tumor subtype comparisons (Baptiste et al., 1989; Birch et al.,
1990; Durmaz et al., 2011; Gold et al., 1994; Hall et al., 2017; Johnson,
Annegers, Frankowski, Spitz, & Buffler, 1987; Rankin et al., 2008; Sun,
Overvad, & Olsen, 2014). Here, we observed an excess of neurological
anomalies among patients diagnosed with CNS tumors and provided
additional information on relationships between the congenital anomaly
andprimary tumor type. Increased cancer riskswere observed for specific
conditions in previous studies, including spina bifida, hydrocephalus, and
congenitalmalformationsof the spinal cord (Aghaet al., 2005; Fisher et al.,
2012; Narod et al., 1997). We found eight patients with spina bifida,
hydrocephalus, and Arnold–Chiari malformations in our cohort, but there
was not statistically significant evidence for enrichment.
Prior studies have also highlighted an increased risk of tumor
development when diagnosed with multiple anomalies (Agha et al.,
2005; Altmann et al., 1998; Bjorge et al., 2008). We found that 5% (7)
of our patients had more than one congenital anomaly, but we did not
FIGURE 1 Scatter plots showing the observed-to-expected (O/E) prevalence ratios by primary tumor and congenital anomaly subtype. O:
observed frequency, E: expected frequency calculated from prevalence rate of the anomaly in the entire study population, 95%CI: 95%
confidence interval, CNS: central nervous system, PNS: peripheral nervous system, STS: soft tissue sarcoma. O/E ratio noted with a (•) with
error bars denoting the 95% confidence interval. †, Indicates no O/E ratio or 95% confidence interval plotted when the observed
frequency = 0. Dotted line represents an O/E ratio of 1.0. Gray bars with (*) indicates p < 0.05
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find evidence for an enrichment of children or adolescents with
multiple congenital anomalies amongst our cancer patients. A recent
data-linkage study also reported a significantly increased rate of
childhood cancer among children with anomalies at younger ages
(Janitz et al., 2016). Here, we demonstrated an excess of congenital
anomalies among patients diagnosed with their primary tumor <5
years of age, with most of this excess attributable to the male
subgroup.
Certain congenital anomalies already have established associa-
tions with neurological malignancies. For example, Neurofibromatosis
type 1 increases a patient’s risk for optic gliomas, malignant peripheral
nerve sheath tumors, and other gliomas (Korf, 2000). Previous studies
have reported associations between CNS tumors and congenital
anomalies, but there were not enough cases to evaluate associations
between specific histologic subtypes or congenital anomaly condition
(Botto et al., 2013; Jones et al., 1995). Here, despite our small sample
size, we observed a non-significant, but consistent, excess for gliomas
with neurological structural defects and movement disorders and for
embryonal tumors with developmental delay. While the subgroups
have small numbers that can make these results unstable, Table 3
shows that each subgroup had a similar relative effect size and that the
overall association is not being driven by one subgroup. In addition,
these subgroup results for gliomas and embryonal tumors are
consistent with associations to birth defects previously reported
(Bailey et al., 2017; Mallol-Mesnard et al., 2008; Partap, MacLean, Von
Behren, Reynolds, & Fisher, 2011). Further collaboration and
development of larger pediatric cohorts is warranted in order to
attain the necessary power to discern the absolute and relative risk of
neurological tumor development with the congenital neurocognitive
anomalies listed here.
We also observed evidence of an excess of congenital anomalies
among male cancer patients, especially in males diagnosed with their
primary tumor <5 years of age. A male excess was observed in a
retrospective study of birth defects, but this was driven by
hypospadias and not observed among neurological anomalies (Botto
et al., 2013). There were a limited number of sex-specific congenital
anomalies in our study, and therefore sex-specific analyses conducted
in previous studies could not be replicatedwith our study population. A
previous study by Fisher et al. (2012) found no significant differences
by sex regardless of congenital anomaly or tumor indication, but a
Canadian linkage study reported a significant excess of male cancer
patients among children with a congenital abnormality compared to
those without (57% vs. 51%, p < 0.001) (Agha et al., 2005). An overall
excess of males diagnosed with childhood cancers has also been
previously reported, with male gender cited as a potential risk
factor for development of brain tumors in a pediatric population
TABLE 3 Comparison of observed to expected frequencies for neurological tumor and neurological anomaly subtype
All neurological anomalies Developmental delay Structural defects Movement disorders
CNS tumor subtype O E O/E (95%CI) O E O/E (95%CI) O E O/E (95%CI) O E O/E (95%CI)
Astrocytoma 8 13.5 0.59 (0.28–1.13) 2 3.6 0.56 (0.09–1.84) 0 0.7 – 6 8.8 0.68 (0.28–1.42)
Embryonal 7 5.4 1.30 (0.57–2.56) 3 1.4 2.14 (0.55–5.83) 0 0.2 – 4 3.4 1.18 (0.37–2.84)
Ependymoma 2 3.6 0.56 (0.09–1.84) 1 1.0 1.00 (0.05–4.93) 0 0.2 – 1 2.3 0.43 (0.02–2.14)
Glioma 6 4.0 1.50 (0.61–3.12) 0 0.9 – 1 0.2 5.00 (0.25–24.67) 5 2.6 1.92 (0.70–4.26)
Other 13 7.7 1.69 (0.94–2.82) 4 1.9 2.11 (0.67–5.08) 1 0.3 3.33 (0.17–16.44) 8 4.8 1.67 (0.77–3.17)
TABLE 4 Comparison of observed to expected frequencies by gender for congenital anomalies and age at primary tumor diagnosis
Male Female
O E O/E (95%CI) O E O/E (95%CI)
Any congenital anomaly 88 81.0 1.09 (0.88–1.33) 53 59.6 0.89 (0.67–1.15)
Neurological 47 39.9 1.18 (0.88–1.55) 27 29.6 0.91 (0.61–1.31)
Cardiovascular 16 14.3 1.12 (0.66–1.78) 12 10.8 1.11 (0.60–1.89)
Gastrointestinal/genitourinary 17 11.3 1.51 (0.91–2.36) 5 8.4 0.60 (0.22–1.32)
Musculoskeletal 6 7.6 0.79 (0.32–1.64) 9 5.8 1.56 (0.76–2.85)
Other 8 5.5 1.45 (0.68–2.76) 3 4.1 0.72 (0.19–1.99)
Age at diagnosis (y)
<5 39 29.0 1.35 (0.97–1.82) 14 16.2 0.86 (0.49–1.42)
5–9 14 20.6 0.68 (0.39–1.11) 12 11.1 1.08 (0.59–1.84)
10–14 17 21.1 0.81 (0.49–1.26) 15 14.9 1.01 (0.59–1.62)
15+ 18 17.4 1.03 (0.63–1.60) 12 10.8 1.11 (0.60–1.89)
O, observed frequency; E, expected frequency calculated with the prevalence rate of the anomaly in the entire study population; 95%CI, 95% confidence
interval.
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(Johnson et al., 2014). Our study continues to support an increased
burden of congenital conditions among males, highlighting the need
for further research investigating the possible underlying mechanisms
attributing to this sex disparity.
Studies have also consistently reported significant associations
between neurological anomalies and CNS tumors (Altmann et al.,
1998; Bjorge et al., 2008; Sun,Warrington et al., 2014;Windham et al.,
1985). This potentially highlights oncogenesis as a continuum of
abnormal development in these patients (Mili, Lynch et al., 1993).
Arising from the neuroectoderm, the human brain is actively
developing for a much longer period than the other major organs,
beginning early in gestation and continuing to develop up to 3 years
after birth (Rice & Barone, 2000). Studies have also reported
conflicting associations of head circumference with childhood cancer
(Bjorge et al., 2013; Samuelsen, Bakketeig, Tretli, Johannesen, &
Magnus, 2006). There were only two indications of macrocephaly in
our study population, limiting our ability to further investigate its
association with other patient demographic information.
While not significant, our results suggest an increased prevalence
of congenital anomalies and pediatric neurological tumors in males
compared to females, which may have origins in developmental
differences. Multiple studies have substantiated the importance of
developmental genes in embryogenesis and their potential role in
tumor development (Birch, 1999; Moore, 2009). Comparison of the
mechanisms of sexual differentiation and oncogenesis reveals a large
overlap in the processes important to both, including but not limited to:
DNA methylation, differentiation, cell migration, proliferation, and
apoptosis (Sun, Warrington, & Rubin, 2012). In addition to gross
differences in themale and female brain (McCarthy et al., 2009;Wilson
and Davies, 2007), model organism and neuroimaging research has
suggested sex differences in synaptic patterns (Ciofi, Leroy, & Tramu,
2006; Greenough, Carter, Steerman, & DeVoogd, 1977) and neuronal
density (Good et al., 2001; Matsumoto & Arai, 1986; Witelson, Glezer,
& Kigar, 1995). Interestingly, male, but not female, astrocytes with
complete loss of NF1 and p53 had greater inactivation of the
retinoblastoma (RB) tumor suppressor gene, resulting in greater risk for
development of mesenchymal glioblastoma (Sun, Overvad et al.,
2014). These data will refine future studies investigating shared
biological processes among neurological anomaly development, sex
differentiation, and oncogenesis.
There are several limitations to this study. Most notably, we did
not have a control group of children without pediatric cancer to
calculate the expected number of congenital anomalies. Furthermore,
the number of CNS tumor cases was higher than leukemia cases in this
cohort, which could be a reflection of referral patterns since the
incidence of leukemia is higher than CNS tumors in the general
population. This finding is likely due to the requirement for
neurosurgical and radiation oncology expertise for CNS tumors
whereas leukemia therapy is largely outpatient without a need for
such interventions. Current international consensus for longitudinal
surveillance of children with a pediatric cancer predisposition is
targeted to conditions that provide a ≥1% risk of cancer. Future clinical
studies must focus on calculating the absolute and relative risk of
cancer in these subgroups of children with specific congenital
anomalies. Translational research will revolve around putative
common mechanisms driving aberrant neurocognitive development
and early childhood CNS tumorigenesis. It is reasonable to think that
such studies would also add important mechanistic insights into the
same tumors in children without congenital anomalies. It is encourag-
ing that outcomes for children with and without congenital anomalies
are generally good (≥80% OS) and similar, at least at this single
institution. This suggests that therapies designed against the
tumorigenic mechanisms in patients with congenital anomalies are
likely to prove efficacious in those without.
In conclusion, this study expands previous associations between
congenital anomalies and pediatric cancer by integrating neuro-
cognitive deficits and movement disorders as well as new insights into
age, gender, and tumor type differences in children with congenital
anomalies and cancer. While sample sizes were small, limiting
statistical significance in most groups, there were many associations
that could be interrogated in larger datasets to more precisely identify
potential subgroups of children that may benefit from increased
surveillance in specialty clinics. For future translational research,
investigations into common mechanisms altering normal development
as well as predisposition to tumorigenesis (e.g., RAS, MAPK, Jumanji
family of histone modifiers) in patient-specific inducible pluripotent
stem cells or other in vivo models could reveal much about the links
between developmental biology and pediatric cancer.
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